Back to results
US 2025/0368656 A1Published application
Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- Enenitrile
AssigneePrincipia Biopharma Inc.
InventorsPasit Phiasivongsa, Kolbot By, Jean Baum
Life of this patent
Estimating the term…
Abstract
Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Claims13
1-8. (canceled)
A process of preparing crystalline Form A of Compound (I):
- wherein C* is a stereochemical center, and
- wherein crystalline Form A is characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 5.6±0.2, 12.7±0.2, 16.5±0.2, 17.0±0.2, 17.7±0.2, 18.7±0.2, 19.2±0.2, 20.7±0.2, 22.2±0.2, and 24.4±0.2,
- the process comprising:
- adding isopropyl acetate to amorphous (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile to form a solution;
- agitating the solution to form a precipitate;
- and
- isolating crystalline Form A by filtration.
4 more elements
10-33. (canceled)
(canceled)
Dependencies are inferred from the claim text.